Biogen stock: buy or sell?

BIIB stock price: $238.79 1.35% At close on September 20th, 2019

Updated on:
September 20th, 2019


Shares of Biogen grew a nice 1.35% and closed at $238.79.

Biogen Inc. discovers, develops, manufactures, and delivers therapies for the treatment of neurological and neurodegenerative diseases worldwide.

Should I buy Biogen stock?

Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. That's why is so important to define your own trading strategy that matches with your character as inversor. At, we like to use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.

None of our preferred buy setups matches with Biogen stock situation right now, hence this is not a suitable entry point.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This is not a selling recommendation at all, just it's not the best moment to buy if you follow any of these trading strategies.

Is Biogen stock a buy?

Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness. At, we collected 15 ratings published for BIIB stock in the last month.

Is BIIB a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-7-24Canaccord Genuityn/aHold
2019-6-28Piper Jaffray CompaniesOverweightNeutral
2019-5-9Barclaysn/aEqual Weight
2019-4-24JPMorgan Chase & Co.n/aHold
2019-4-10Raymond Jamesn/aMarket Perform
2019-3-27Cantor Fitzgeraldn/aHold
2019-3-25Royal Bank of Canadan/aSector Perform
2019-3-25HC Wainwrightn/aBuy
2019-3-22UBS GroupBuyNeutral
2019-3-22Morgan StanleyOverweightUnderweight

Biogen stock analysis

Daily outlook

Shares of Biogen ended today at $238.79 and grew a nice 1.35%.

Biogen shares grew 1.35% to $238.79 today. Since Sep/10 when BIIB stock price broke up the SMA100d line, it gained $8.79 (3.82%). Since SMA50d and SMA100d crossed up on Aug/9, BIIB price climbed $0.56 per share (0.24%).

BIIB stock chart (daily)

Weekly outlook

After boosting a phenomenal 5.10% in a week last week, Biogen closed this week at $238.79 and gained a tiny 0.91%. With this, it's been 3 green weeks in a row, gaining $19.04 or 8.43%.

Since price and 40-weeks moving average lines crossed down by mid March, BIIB fell $-91.08 per share (-27.61%). Trading stocks that are below the 40-weeks (that is, 200-days) moving average mark is not recommended by many experts, as it indicates that the stock has not enough institutional support.

BIIB stock chart (weekly)

Biogen stock price history

Biogen stock went public on September 17th, 1991 with a price of $3.001. Since then, BIIB stock grew a 7,859.70%, with a yearly average of 280.70%. If you had invested right after BIIB's IPO a $1,000 in Biogen stock in 1991, it would worth $78,597.00 today.

1: Adjusted price after possible price splits or reverse-splits.

Biogen stock historical price chart

BIIB stock reached 52-week highs on October at $358.41, and all-time highs 2015-03-20 with a price of 480.18.

Biogen stock price target is $268.40

Nobody can reliably foresee how stock prices may evolve in the future. However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. For the last 30 days we found 8 price predictions for Biogen stock:
BIIB stock price predictions
DateAnalyst / BrokerActionPrevious targetCurrent targetDiff
2019-7-24Canaccord GenuityRaises Target$275.00$285.003.6%
2019-5-9BarclaysLowers Target$250.00$245.00-2%
2019-3-27Cantor FitzgeraldReiteratesn/a$250.00-
2019-3-25Royal Bank of CanadaLowers Targetn/a$236.00-
2019-3-25HC WainwrightLowers Target$363.00$300.00-17.4%
2019-3-22NomuraLowers Target$420.00$320.00-23.8%
2019-3-22GuggenheimSet Price Targetn/a$236.00-
(in average)$327.00$268.40-18.0%
Moving in a range from $320.00 and $236.00, the price forecast for BIIB stock is $268.40. In average, analysts' outlook on BIIB price forecast is negative, downsizing the prediction by a -18.00% from previous estimations.

Financials and fundamental analysis

Earnings date and Earnings per Share

Since April, when Biogen presented its last earnings report, it . As soon as we get its posted EPS from the earnings report, we will update this review.
BIIB earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise

Annual financial results

Compared to 2017, last anual revenues report draw a phenomenal increase of 9.61% to $13,452.90 M USD. When comparing 2018 vs 2017, aligned with this, profit margin (that is, the net income divided by revenues) boosted a 12.25% to 32.93%.

Biogen fiscal year ends in December, and to compare its evolution since then, we estimate annual sales and income figures by adding results from the last 4 quarters. This is called TTM (or Twelve Trailing Months). So, Biogen TTM sales up to March 2019 were $13,811.60 and income $4,666.60 million dollars. If we compare this TTM figures with the last reported annuality, we can esteem Biogen business evolution since December 2018: Annual turnover up to March, compared to lastest yearly report, grew a tiny 2.67%. Regarding profit margin, Biogen stayed stable 0.85% to 32.93%

BIIB annual Sales and Income evolution
2013$5,860 M-$1,860 M31.7%-
2014$9,703 M65.59%$2,935 M30.2%57.78%
2015$10,764 M10.93%$3,547 M33.0%20.86%
2016$11,449 M6.36%$3,703 M32.3%4.39%
2017$12,274 M7.21%$2,539 M20.7%-31.43%
2018$13,453 M9.61%$4,431 M32.9%74.50%
TTM $13,812 M2.67%$4,667 M33.8%5.32%

Quarterly financial results

Biogen posted $3,489.80 million in revenues for 2019-Q1, a -1.04% decline compared to previous quarter. Reported quarter earnings marked $1,408.80 M with a profit margin of 40.37%. Profit margin rocketed a 13.52% compared to previous quarter when profit margin was 26.85%. When comparing revenues to same quarter last year, Biogen sales marked a cool growth and climbed a 11.46%.
BIIB quarterly Sales and Income evolution
2017-Q2$2,730 M-$863 M31.6%-
2017-Q3$2,770 M1.47%$1,230 M44.4%42.56%
2017-Q4$3,307 M19.39%$-297 M-9.0%-124.18%
2018-Q1$3,131 M-5.32%$1,173 M37.5%-494.38%
2018-Q2$3,357 M7.20%$867 M25.8%-26.11%
2018-Q3$3,439 M2.46%$1,444 M42.0%66.67%
2018-Q4$3,526 M2.54%$947 M26.8%-34.45%
2019-Q1$3,490 M-1.04%$1,409 M40.4%48.80%

Biogen ownership

When you are planning to buy shares of a company, it's worth to check its ownership structure.

Biogen shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 0.47% of all shares.

Bearish positions for BIIB stock account 0.00%, no big difference from last month.

The following table compares ownership indicators for other stocks related to Biogen:

Market cap$44.0 B$106.1 B$167.9 M$118.1 B$8.4 B
Total shares184.5 M1,480.0 M48.1 M599.7 M24.7 M
Float shares184.0 M1,480.0 M39.5 M598.3 M21.3 M
  - Institutional holdings (%)93.4%71.9%112.3%81.9%78.0%
  - Insider holdings (%)0.5%0.1%1.8%0.2%14.6%
Shares in short selling0.0%0.0%0.0%0.0%0.0%

Biogen summary

Friday, September 20th, 2019
Day range$234.31 - $242.21
Previous close$235.62
Session gain1.35%
Average true range$5.99
50d mov avg$232.47
100d mov avg$231.67
200d mov avg$263.76
Daily pattern
Weekly pattern

Biogen performance

Performance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. For Biogen, the benchmark is made against AbbVie, Acorda Therapeutics, Amgen, Bio-Rad Laboratories, Celgene, Gilead Sciences, , Pfizer, Sangamo Therapeutics and .
ACORAcorda Therapeuti...-53.40%-73.42%-80.82%
BIOBio-Rad Laborator...11.54%11.17%13.82%
GILDGilead Sciences-3.38%6.14%-8.74%
SGMOSangamo Therapeut...6.83%19.57%-32.51%

Biogen competitors

One check before investing in any stock is to have a look a list of its competitors, in this case for Biogen. We selected 10 companies as Biogen competitors as they are in the same industry or have similar market objectives.

Latest Biogen stock news